FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Front Vet Sci / Tenogenically Induced Allogeneic Peripheral Blood Mesenchyma...
Frontiers in veterinary science2017; 4; 158; doi: 10.3389/fvets.2017.00158

Tenogenically Induced Allogeneic Peripheral Blood Mesenchymal Stem Cells in Allogeneic Platelet-Rich Plasma: 2-Year Follow-up after Tendon or Ligament Treatment in Horses.

Abstract: Poor healing of tendon and ligament lesions often results in early retirement of sport horses. Therefore, regenerative therapies are being explored as potentially promising treatment for these injuries. In this study, an intralesional injection was performed with allogeneic tenogenically induced mesenchymal stem cells and platelet-rich plasma 5-6 days after diagnosis of suspensory ligament (SL) (n = 68) or superficial digital flexor tendon (SDFT) (n = 36) lesion. Clinical, lameness and ultrasonographic evaluation was performed at 6 and 12 weeks. Moreover, a survey was performed 12 and 24 months after treatment to determine how many horses were competing at original level and how many were re-injured. At 6 weeks, 88.2% of SL (n = 68) and 97.3% of SDFT lesions (n = 36) demonstrated moderate ultrasonographic improvement. At 12 weeks, 93.1% of SL (n = 29) and 95.5% of SDFT lesions (n = 22) improved convincingly. Moreover, lameness was abolished in 78.6% of SL (n = 28) and 85.7% (n = 7) of SDFT horses at 12 weeks. After 12 months (n = 92), 11.8% of SL and 12.5% of SDFT horses were re-injured, whereas 83.8 of SL and 79.2% of SDFT returned to previous performance level. At 24 months (n = 89) after treatment, 82.4 (SL) and 85.7% (SDFT) of the horses returned to previous level of performance. A meta-analysis was performed on relevant published evidence evaluating re-injury 24 months after stem cell-based [17.6% of the SL and 14.3% of the SDFT group (n = 89)] versus conventional therapies. Cell therapies resulted in a significantly lower re-injury rate of 18% [95% confidence interval (CI), 0.11-0.25] 2 years after treatment compared to the 44% re-injury rate with conventional treatments (95% CI, 0.37-0.51) based on literature data (P < 0.0001).
Get Full Text
Publication Date: 2017-09-26 PubMed ID: 29018808PubMed Central: PMC5622984DOI: 10.3389/fvets.2017.00158Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The study focuses on assessing the efficacy of allogeneic mesenchymal stem cells and platelet-rich plasma in treating tendon or ligament injuries in horses. The results highlight that this method of treatment has a significantly lower re-injury rate (18%) compared to conventional treatments (44%) two years after the procedure.

Introduction

  • The research aims to find effective regenerative therapies for tendon and ligament lesions in sport horses, which often lead to their early retirement.
  • The researchers have used a mixture of allogeneic (from a different individual of the same species) mesenchymal stem cells and platelet-rich plasma, injected directly into the injured area for treatment.

Methodology

  • An intralesional injection was conducted with the said mixture within 5-6 days after diagnosing the lesion.
  • Horses with suspensory ligament (SL) or superficial digital flexor tendon (SDFT) were chosen for this study.
  • Multiple evaluation parameters were checked before and after treatment such as clinical conditions, lameness, ultrasonographic evaluation etc., spread across specific time intervals.
  • Also, a survey was done at 12 and 24 months post-treatment to check the number of horses that returned to their original performance level and those that were re-injured.

Results

  • A significant ultrasonographic improvement was observed in 88.2% of SL and 97.3% of SDFT lesions 6 weeks after the treatment.
  • This improvement was even more pronounced at 12 weeks with 93.1% of SL and 95.5% of SDFT lesions showing drastic improvement.
  • Lameness was also significantly reduced in 78.6% of SL and 85.7% of SDFT horses by the 12th week.
  • At the end of a year, the re-injury rate was found to be 11.8% and 12.5% for SL and SDFT horses respectively. The percentage of horses returning to their original performance level was 83.8% for SL and 79.2% for SDFT.
  • 24 months after treatment, the performance levels maintained consistency with 82.4% (SL) and 85.7% (SDFT) horses maintaining previous performance level.
  • A meta-analysis comparing stem cell-based therapies and traditional approaches revealed the re-injury rates to be substantially lower in the former category.

Conclusion

  • Based on the results drawn from this research, it can be concretely stated that the use of allogeneic mesenchymal stem cell and platelet-rich plasma treatment offers a significantly lesser re-injury rate as compared to the conventional modes of treatment.
  • This study suggests a promising future for stem cell-based therapies in horse injury treatments, significantly enhancing their chances of complete recovery and return to sustainable performance levels.

Cite This Article

APA
Beerts C, Suls M, Broeckx SY, Seys B, Vandenberghe A, Declercq J, Duchateau L, Vidal MA, Spaas JH. (2017). Tenogenically Induced Allogeneic Peripheral Blood Mesenchymal Stem Cells in Allogeneic Platelet-Rich Plasma: 2-Year Follow-up after Tendon or Ligament Treatment in Horses. Front Vet Sci, 4, 158. https://doi.org/10.3389/fvets.2017.00158

Publication

Frontiers in veterinary science
ISSN: 2297-1769
NlmUniqueID: 101666658
Country: Switzerland
Language: English
Volume: 4
Pages: 158

Researcher Affiliations

Beerts, Charlotte
  • Global Stem Cell Technology, ANACURA Group, Evergem, Belgium.
Suls, Marc
  • Equine Veterinary Practice Dr. Suls, Nederweert, Netherlands.
Broeckx, Sarah Y
  • Global Stem Cell Technology, ANACURA Group, Evergem, Belgium.
Seys, Bert
  • Equine Veterinary Practice Dr. Suls, Nederweert, Netherlands.
Vandenberghe, Aurélie
  • Global Stem Cell Technology, ANACURA Group, Evergem, Belgium.
Declercq, Jeroen
  • Veterinary Practitioner, Oudenaarde, Belgium.
Duchateau, Luc
  • Faculty of Veterinary Medicine, Department of Comparative Physiology and Biometrics, Ghent University, Merelbeke, Belgium.
Vidal, Martin A
  • Cave Creek Equine Surgical & Imaging Center, Phoenix, AZ, United States.
Spaas, Jan H
  • Global Stem Cell Technology, ANACURA Group, Evergem, Belgium.

References

This article includes 48 references
  1. Thorpe CT, Clegg PD, Birch HL. A review of tendon injury: why is the equine superficial digital flexor tendon most at risk?. Equine Vet J (2010) 42:174–80.
    doi: 10.2746/042516409X480395pubmed: 20156256google scholar: lookup
  2. Murray RC, Dyson SJ, Tranquille C, Adams V. Association of type of sport and performance level with anatomical site of orthopaedic injury diagnosis. Equine Vet J (2006) 36:411–6.
    doi: 10.1111/j.2042-3306.2006.tb05578.xpubmed: 17402457google scholar: lookup
  3. Spaas JH, Guest DJ, Van de Walle GR. Tendon regeneration in human and equine athletes: Ubi Sumus-Quo Vadimus (where are we and where are we going to)?. Sports Med (2012) 42:871–90.
    doi: 10.2165/11635390-000000000-00000pubmed: 22963225google scholar: lookup
  4. Richardson CE, Dudhia J, Clegg PD, Smith R. Stem cells in veterinary medicine: attempts at regenerating equine tendon after injury. Trends Biotechnol (2007) 25:409–16.
    doi: 10.1016/j.tibtech.2007.07.009pubmed: 17692415google scholar: lookup
  5. Baxter GM. Tendon and ligament injuries and disease. In: Baxter GM, editor. Adams and Stashak’s Lameness in Horses. Chichester, FL: Wiley-Blackwell; (2012). p. 927–38.
  6. Beerts C, Seifert C, Zimmerman M, Felix E, Suls M, Mariën T. Desmitis of the accessory ligament of the equine deep digital flexor tendon: a regenerative approach. J Tissue Sci Eng (2013) 4:1–7.
    doi: 10.4172/2157-7552.1000125google scholar: lookup
  7. Dakin SG, Dudhia J, Smith RKW. Resolving an inflammatory concept: the importance of inflammation and resolution in tendinopathy. Vet Immunol Imunopathol (2014) 158:121–7.
    doi: 10.1016/j.vetimm.2014.01.007pmc: PMC3991845pubmed: 24556326google scholar: lookup
  8. James R, Kesturu G, Balian G, Chhabra B. Tendon: biology, biomechanics, repair, growth factors, and evolving treatment options. J Hand Surg Am (2008) 33:102–12.
    doi: 10.1016/j.jhsa.2007.09.007pubmed: 18261674google scholar: lookup
  9. McCullagh KG, Goodship AE, Silver IA. Tendon injuries and their treatment in the horse. Vet Rec (1979) 105:54–7.
    doi: 10.1136/vr.105.3.54pubmed: 400209google scholar: lookup
  10. Obaid H, Connell D. Cell therapy in tendon disorders: what is the current evidence?. Am J Sports Med (2010) 38:2123–32.
    doi: 10.1177/0363546510373574pubmed: 20699425google scholar: lookup
  11. Williams IF, Heaton A, McCullagh KG. Cell morphology and collagen types in equine tendon scar. Res Vet Sci (1980) 28:302–10.
    pubmed: 7414083
  12. Carvalho AM, Badial PR, Alvarez LEC, Yamada AL, Borges AS, Deffune E. Equine tendonitis therapy using mesenchymal stem cells and platelet concentrates: a randomized controlled trial. Stem Cell Res Ther (2013) 4:1–13.
    doi: 10.1186/scrt236pmc: PMC3854756pubmed: 23876512google scholar: lookup
  13. Smith RK, Werling NJ, Dakin SG, Alam R, Goodship AE, Dudhia J. Beneficial effects of autologous bone marrow-derived mesenchymal stem cells in naturally occurring tendinopathy. PLoS One (2013) 8:e75697.
    doi: 10.1371/journal.pone.0075697pmc: PMC3783421pubmed: 24086616google scholar: lookup
  14. Van Loon VJ, Scheffer CJ, Genn HJ, Hoogendoorn AC, Greve JW. Clinical follow-up of horses treated with allogeneic equine mesenchymal stem cells derived from umbilical cord blood for different tendon ad ligament disorders. Vet Q (2014) 34:92–7.
    doi: 10.1080/01652176.2014.949390pubmed: 25072527google scholar: lookup
  15. Ricco S, Renzi S, Del Bue M, Conti V, Merli E, Ramoni R. Allogeneic adipose tissue-derived mesenchymal stem cells in combination with platelet rich plasma are safe and effective in the therapy of superficial digital flexor tendonitis in the horse. Int J Immunopathol Pharmacol (2013) 26:61–8.
    doi: 10.1177/03946320130260S108pubmed: 24046950google scholar: lookup
  16. Awad HA, Boivin GP, Dressler MR, Smith FN, Young RG, Butler DL. Repair of patellar tendon injuries using a cell-collagen composite. J Orthop Res (2003) 21:420–31.
    doi: 10.1016/S0736-0266(02)00163-8pubmed: 12706014google scholar: lookup
  17. Harris MT, Butler DL, Boivin GP, Florer JB, Schantz EJ, Wenstrup RJ. Mesenchymal stem cells used for rabbit tendon repair can form ectopic bone and express alkaline phosphatase activity in constructs. J Orthop Res (2004) 22:998–1003.
    doi: 10.1016/j.orthres.2004.02.012pubmed: 15304271google scholar: lookup
  18. Fahy N, de Vries-van Melle ML, Lehmann J, Wei W, Grotenhuis N, Farrell E. Human osteoarthritic synovium impactes chondrogenic differentiation of mesenchymal stem cells via macrophage polarisation state. Osteoarthritis Cartilage (2014) 22:1167–75.
    doi: 10.1016/j.joca.2014.05.021pubmed: 24911520google scholar: lookup
  19. Broeckx S, Zimmerman M, Aerts D, Seys B, Suls M, Mariën T. Tenogenesis of equine peripheral blood-derived mesenchymal stem cells: in vitro versus in vivo. J Tissue Sci Eng (2012) 11:1–6.
    doi: 10.4172/2157-7552.S11-001google scholar: lookup
  20. Broeckx S, Zimmerman M, Crocetti S, Suls M, Mariën T, Ferguson SJ. Regenerative therapies for equine degenerative joint disease: a preliminary study. PLoS One (2014) 9:e85917.
    doi: 10.1371/journal.pone.0085917pmc: PMC3896436pubmed: 24465787google scholar: lookup
  21. Gomiero C, Bertolutti G, Martinello T, Van Bruaene N, Broeckx SY, Patruno M. Tenogenic induction of equine mesenchymal stem cells by means of growth factors and low level laser therapy. Vet Res Commun (2016) 40:39–48.
    doi: 10.1007/s11259-016-9652-ypubmed: 26757735google scholar: lookup
  22. Spaas JH, De Schauwer C, Cornillie P, Meyer E, Van Soom A, Van de Walle GR. Culture and characterization of equine peripheral blood mesenchymal stromal cells. Vet J (2013) 195:107–13.
    doi: 10.1016/j.tvjl.2012.05.006pubmed: 22717781google scholar: lookup
  23. Spaas JH, Broeckx SY, Chiers K, Ferguson SJ, Casarosa M, Van Bruaene N. Chondrogenic priming at reduced cell density enhances cartilage adhesion of equine allogeneic MSCs – a loading sensitive phenomenon in an organ culture study with 180 explants. Cell Physiol Biochem (2015) 37:651–65.
    doi: 10.1159/000430384pubmed: 26344791google scholar: lookup
  24. Vandenberghe A, Broeckx SY, Beerts C, Seys B, Zimmerman M, Verweire I. Tenogenically induced allogeneic mesenchymal stem cells for the treatment of proximal suspensory ligament desmitis in a horse. Front Vet Sci (2015) 2:49.
    doi: 10.3389/fvets.2015.00049pmc: PMC4672201pubmed: 26664976google scholar: lookup
  25. Araki J, Jona M, Eto H, Aoi N, Kato H, Suga H. Optimized preparation method of platelet-concentrated plasma and noncoagulating platelet-derived factor concentrates: maximization of platelet concentration and removal of fibrinogen. Tissue Eng Part C Methods (2012) 18:176–85.
    doi: 10.1089/ten.TEC.2011.0308pmc: PMC3285602pubmed: 21951067google scholar: lookup
  26. Marr CM, McMillan I, Boyd JS, Wright NG, Murray M. Ultrasonographic and histopathological findings in equine superficial digital flexor tendon injury. Equine Vet J (1993) 25:23–9.
    doi: 10.1111/j.2042-3306.1993.tb02896.xpubmed: 8422880google scholar: lookup
  27. Del Bue M, Ricco S, Ramoni R, Conti V, Gnudi G, Grolli S. Equine adipose-tissue derived mesenchymal stem cells and platelet concentrates: their association in vitro and in vivo. Vet Res Commun (2008) 32:51–5.
    doi: 10.1007/s11259-008-9093-3pubmed: 18683070google scholar: lookup
  28. Godwin EE, Young NJ, Dudhia J, Beamish IC, Smith RKW. Implantation of bone marrow-derived mesenchymal stem cells demonstrates improved outcome in horses with overstrain injury of the superficial digital flexor tendon. Equine Vet J (2012) 44:25–32.
    doi: 10.1111/j.2042-3306.2011.00363.xpubmed: 21615465google scholar: lookup
  29. Dyson SJ. Medical management of superficial digital flexor tendonitis: a comparative study in 219 horses (1992-2000). Equine Vet J (2004) 36:415–9.
    doi: 10.2746/0425164044868422pubmed: 15253082google scholar: lookup
  30. Guest DJ, Smith MRW, Allen WR. Monitoring the fate of autologous and allogeneic mesenchymal progenitor cells injected into the superficial digital flexor tendon of horses: preliminary study. Equine Vet J (2008) 40:178–81.
    doi: 10.2746/042516408X276942pubmed: 18267891google scholar: lookup
  31. Carrade DD, Owens SD, Galuppo LD, Vidal MA, Ferraro GL, Librach F. Clinicopathologic findings following intra-articular injection of autologous and allogeneic placentally derived equine mesenchymal stem cells in horses. Cytotherapy (2011) 13:419–30.
    doi: 10.3109/14653249.2010.536213pubmed: 21105841google scholar: lookup
  32. Carrade DD, Lame MW, Kent MS, Clark KC, Walker NJ, Borjesson DL. Comparative analysis of the immunomodulatory properties of equine adult-derived mesenchymal stem cells. Cell Med (2012) 4:1–11.
    doi: 10.3727/215517912X647217pmc: PMC3495591pubmed: 23152950google scholar: lookup
  33. Carrade DD, Borjesson DL. Immunomodulation by mesenchymal stem cells in veterinary species. Comp Med (2013) 63:207–17.
    pmc: PMC3690426pubmed: 23759523
  34. Kol A, Wood JA, Carrade Holt DD, Gillette JA, Bohannon-Worsley LK, Puchalski SM. Multiple intravenous injections of allogeneic equine mesenchymal stem cells do not induce a systemic inflammatory response but do alter lymphocyte subsets in healthy horses. Stem Cell Res Ther (2015) 6:73.
    doi: 10.1186/s13287-015-0050-0pmc: PMC4446064pubmed: 25888916google scholar: lookup
  35. Broeckx S, Borena BM, Zimmerman M, Mariën T, Seys B, Suls M. Intravenous application of allogenic peripheral blood-derived mesenchymal stem cells: a safety assessment in 291 equine recipients. Curr Stem Cell Res Ther (2014) 9:452–7.
    doi: 10.2174/1574888X09666140220003847pubmed: 24548143google scholar: lookup
  36. Joswig AJ, Mitchell A, Cummings KJ, Levine GJ, Gregory CA, Smith R. Repeated intra-articular injection of allogeneic mesenchymal stem cells causes an adverse response compared to autologous cells in the equine model. Stem Cell Res Ther (2017) 8:42.
    doi: 10.1186/s13287-017-0503-8pmc: PMC5329965pubmed: 28241885google scholar: lookup
  37. Caron JP. Osteoarthritis. In: Ross MW, Dyson SJ, editors. Diagnosis and Management of Lameness in the Horse. St. Louis, MO: Elsevier Saunders; (2011). 666 p..
  38. Ardenaz N, Vazquez FJ, Romero A, Remacha AR, Barrachina L, Sanz A. Inflammatory response to the administration of mesenchymal stem cells in an equine experimental model: effect of autologous, and single and repeat doses of pooled allogeneic cells in healthy joints. Vet Res (2016) 12:65.
    doi: 10.1186/s12917-016-0692-xpmc: PMC4815220pubmed: 27029614google scholar: lookup
  39. Owens SD, Kol A, Walker NJ, Borjesson D. Allogeneic mesenchymal stem cell treatment induces specific alloantibodies in horses. Stem Cells Int (2016) 2016:5830103.
    doi: 10.1155/2016/5830103pmc: PMC5018342pubmed: 27648075google scholar: lookup
  40. Berglund AK, Schnabel LV. Allogeneic major histocompatibility complex-mismatched equine bone marrow-derived mesenchymal stem cells are targeted for death by cytotoxic anti-major histocompatibility complex antibodies. Equine Vet J (2017) 49:539–44.
    doi: 10.1111/evj.12647pmc: PMC5425313pubmed: 27862236google scholar: lookup
  41. Pezzanite LM, Fortier LA, Antczak DF, Cassano JM, Brosnahan MM, Miller D. Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo. Stem Cell Res Ther (2015) 6:54.
    doi: 10.1186/s13287-015-0053-xpmc: PMC4414005pubmed: 25889095google scholar: lookup
  42. Berglund AK, Fischer MB, Cameron KA, Poole EJ, Schnabel LV. Transforming growth factor-β2 downregulates major histocompatibility complex (MHC) I and MHC II surface expression on equine bone marrow-derived mesenchymal stem cells without altering other phenotypic cell surface markers. Front Vet Sci (2017) 4:84.
    doi: 10.3389/fvets.2017.00084pmc: PMC5466990pubmed: 28660198google scholar: lookup
  43. Boswell SG, Schnabel LV, Mohammed HO, Sundman EA, Minas T, Fortier LA. Increasing platelet concentrations in leukocyte-reduced platelet-rich plasma decrease collagen gene synthesis in tendons. Am J Sports Med (2014) 42:42–9.
    doi: 10.1177/0363546513507566pubmed: 24136860google scholar: lookup
  44. McCarrel TM, Minas T, Fortier LA. Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy. J Bone Joint Surg Am (2012) 3:e143.
    doi: 10.2106/JBJS.L.00019pubmed: 23032594google scholar: lookup
  45. Riboh JC, Saltzman BM, Yanke AB, Fortier L, Cole BJ. Effect of leukocyte concentration on the efficacy of platelet-rich plasma in the treatment of knee osteoarthritis. Am J Sports Med (2016) 44:792–800.
    doi: 10.1177/0363546515580787pubmed: 25925602google scholar: lookup
  46. Toricelli P, Fini M, Filardo G, Tschon M, Pischedda M, Pacorini A. Regenerative medicine for the treatment of musculoskeletal overuse injuries in competition horses. Int Orthop (2011) 35:1569–76.
    doi: 10.1007/s00264-011-1237-3pmc: PMC3174295pubmed: 21394594google scholar: lookup
  47. Cowles RR, Johnson LD, Holoway PM. Proximal suspensory desmitis: a retrospective study. Proceed Am Assoc Eq Pract (1994) 4:183–5.
  48. Bosch G, van Weeren PR, Barneveld A, van Schie HTM. Computerised analysis of standardised ultrasonographic images to monitor the repair of surgically created core lesions in equine superficial digital flexor tendons following treatment with intratendinous platelet rich plasma or placebo. Vet J (2011) 187:92–8.
    doi: 10.1016/j.tvjl.2009.10.014pubmed: 19932036google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.